Trillium Therapeutics Inc (NASDAQ:TRIL) (TSE:TR) shares saw unusually-strong trading volume on Thursday . Approximately 4,766 shares changed hands during mid-day trading, a decline of 100% from the previous session’s volume of 1,036,931 shares.The stock last traded at $0.40 and had previously closed at $0.41.

A number of research analysts have commented on TRIL shares. Zacks Investment Research raised shares of Trillium Therapeutics from a “hold” rating to a “buy” rating and set a $0.75 target price on the stock in a research report on Thursday, April 25th. HC Wainwright decreased their target price on shares of Trillium Therapeutics from $10.00 to $4.00 and set a “buy” rating on the stock in a research report on Wednesday, March 13th.

The stock has a market cap of $7.85 million, a P/E ratio of -0.16 and a beta of 2.44.

Hedge funds and other institutional investors have recently bought and sold shares of the business. Jane Street Group LLC acquired a new position in Trillium Therapeutics in the fourth quarter valued at about $43,000. Two Sigma Investments LP acquired a new position in Trillium Therapeutics in the fourth quarter valued at about $35,000. Morgan Stanley lifted its position in Trillium Therapeutics by 25.2% in the third quarter. Morgan Stanley now owns 356,655 shares of the biotechnology company’s stock valued at $2,068,000 after buying an additional 71,860 shares during the last quarter. NEA Management Company LLC lifted its position in Trillium Therapeutics by 68.0% in the first quarter. NEA Management Company LLC now owns 2,100,000 shares of the biotechnology company’s stock valued at $1,386,000 after buying an additional 850,000 shares during the last quarter. Finally, Geode Capital Management LLC lifted its position in Trillium Therapeutics by 164.0% in the fourth quarter. Geode Capital Management LLC now owns 26,627 shares of the biotechnology company’s stock valued at $45,000 after buying an additional 16,541 shares during the last quarter. 33.00% of the stock is currently owned by institutional investors.

WARNING: This news story was published by Watch List News and is the sole property of of Watch List News. If you are accessing this news story on another site, it was stolen and reposted in violation of U.S. & international copyright laws. The correct version of this news story can be read at https://www.watchlistnews.com/trillium-therapeutics-nasdaqtril-sees-unusually-high-trading-volume/3042245.html.

About Trillium Therapeutics (NASDAQ:TRIL)

Trillium Therapeutics Inc, a clinical-stage immuno-oncology company, develops therapies for the treatment of cancer. The company's lead program is TTI-621, a SIRPaFc fusion protein that acts a soluble decoy receptor preventing CD47 from delivering its inhibitory signal, which is in Phase I clinical trials for advanced hematologic malignancies, and solid tumors and mycosis fungoides.

See Also: Swap

Receive News & Ratings for Trillium Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trillium Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.